Bruker takes majority stake in organ-on-a-chip developer MIMETAS
BRKR•Deal terms and integration plans
The deal aims to combine these models with Bruker’s multiomics, NMR, spatial biology, and preclinical imaging to build integrated research workflows.
Financial terms were not disclosed; MIMETAS will keep its brand and management.
Bruker expands into organ-on-a-chip systems
Bruker took a majority stake in MIMETAS, expanding into organ-on-a-chip microphysiological systems for drug discovery and preclinical testing.
MIMETAS’ OrganoPlate platform provides scalable, high-throughput human tissue models designed to improve disease modeling, drug testing, and safety assessment.
